Literature DB >> 26245867

[Hemolytic anemia].

A Tuchscherer1, J Chemnitz.   

Abstract

Hemolytic anemia can be caused by various hereditary or acquired diseases. Classification is usually based on corpuscular or extracorpuscular defects. Beside the anemia, laboratory testing indicates increased lactate dehydrogenase, unconjugated bilirubin and reticulocytes as well as reduced or absent plasma haptoglobin. Knowledge of further diagnostic procedures (e.g., Coombs test, schistocytes, hemoglobin electrophoresis or flow cytometric analysis) leads in many cases to an underlying disease with differentiated therapeutic options. Autoimmune hemolytic anemia (AIHA) is often associated with diseases as HIV, connective tissue disease, lymphomas or malignant tumors and the hemolytic process is preexisting in many cases. Thrombotic microvascular diseases (e.g., thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome) are further important causes of hemolytic anemia which need immediate diagnosis and treatment.

Entities:  

Mesh:

Year:  2015        PMID: 26245867     DOI: 10.1007/s00108-015-3661-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

1.  High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

Authors:  Victor M Moyo; Douglas Smith; Isadore Brodsky; Pamela Crilley; Richard J Jones; Robert A Brodsky
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 2.  Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators.

Authors:  O Pourrat; R Coudroy; F Pierre
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-03-25       Impact factor: 2.435

3.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

4.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

5.  Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.

Authors:  Jens Marcus Chemnitz; Jens Uener; Michael Hallek; Christof Scheid
Journal:  Ann Hematol       Date:  2010-04-27       Impact factor: 3.673

Review 6.  Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.

Authors:  John Chapin; Tsiporah Shore; Peter Forsberg; Garrett Desman; Koen Van Besien; Jeffrey Laurence
Journal:  Clin Adv Hematol Oncol       Date:  2014-09

7.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 8.  Monoclonal antibodies in the treatment of autoimmune cytopenias.

Authors:  Tadeusz Robak
Journal:  Eur J Haematol       Date:  2004-02       Impact factor: 2.997

Review 9.  Cold antibody autoimmune hemolytic anemias.

Authors:  Lawrence D Petz
Journal:  Blood Rev       Date:  2007-09-27       Impact factor: 8.250

Review 10.  How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.

Authors:  Marie Scully; Tim Goodship
Journal:  Br J Haematol       Date:  2014-01-06       Impact factor: 6.998

View more
  1 in total

Review 1.  [Diagnostics and treatment of preoperative anemia].

Authors:  C Rosenthal; C von Heymann; L Kaufner
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.